Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EJMM | ISIN: US59564R7089 | Ticker-Symbol: 5MP
Tradegate
28.03.24
21:52 Uhr
1,330 Euro
-0,030
-2,21 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BIODEXA PHARMACEUTICALS PLC ADR Chart 1 Jahr
5-Tage-Chart
BIODEXA PHARMACEUTICALS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
1,3101,41028.03.

Aktuelle News zur BIODEXA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoExtend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potential7
DoWhy Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?3
DoBiodexa Pharmaceuticals Plc: Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers220Topline Results For Progression-Free Survival Expected In Q2 2024CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ("Biodexa"), an acquisition-focused biopharmaceutical...
► Artikel lesen
18.03.Biodexa Pharmaceuticals files to sell 1.28B shares for holders8
18.03.Biodexa Pharmaceuticals Plc - F-1, Registration statement for certain foreign private issuers4
01.03.Biodexa Pharmaceuticals Plc: Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone326Orally dosed small molecule candidate is designed to reduce/eliminate need for injectable insulinTopline data from Phase 2a program expected by year-endSafety profile established in more than 700 patientsCARDIFF...
► Artikel lesen
23.02.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer3
23.02.What's Going On With Rare/Orphan Disease Focused-Biodexa Pharmaceuticals Stock Friday?2
23.02.Biodexa stock slides 7% amid data for two drug studies3
23.02.Biodexa Reports Positive Phase 1 Trial Results For Diffuse Midline Glioma; Stock Falls 7%1
23.02.Biodexa reports promising phase 1 brain cancer drug results4
23.02.Biodexa Pharmaceuticals PLC: Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update1.042Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall Survival...
► Artikel lesen
14.02.GMBL, LICN and BDRX among pre-market losers4
13.02.Why Is Brain Cancer Focused-Biodexa Pharmaceuticals Stock Trading Higher Today?7
13.02.BDRX, FAMI and UPXI are among pre market gainers4
13.02.Pre-market Movers: Ohmyhome, ARB IOT, Farmmi, Biodexa Pharmaceuticals, G1 Therapeutics657BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.50 A.M. ET).In the Green Ohmyhome Limited (OMH) is up over 351% at $5.51. ARB...
► Artikel lesen
09.02.Biodexa reports glioblastoma patient survival in study9
08.02.Biodexa Pharmaceuticals PLC: Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients362Biodexa Pharmaceuticals PLC Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients CARDIFF, United Kingdom, February 8, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals...
► Artikel lesen
07.02.Biodexa stock jumps on allowance of U.S. patent covering Tolimidone2
07.02.WRK, BDRX and MDAI are among pre market gainers1
Seite:  Weiter >>
65 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1